Early phase clinical trial units (epctu)
Active Awarded Last action
- Contract number
- 75N93022D00019
- Awardee
-
Duke University UEI TP7EK8DZV6N5
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Task orders
- 1 $764,407 obligated
Award facts
- Opportunity
-
- Early Phase Clinical Trial Units (EPCTU) Pre-Solicitation · 75N93020R00023 · Posted Nov 19, 2020
- Combined order value
-
- $764,407 Current, with exercised options
- $1,963,927 Potential, with all options
- Last date to order 48% complete
- IDV ceiling <1% used
- $346,610,277.00
- Award type
- Multiple award
- Who can order
- Only the awarding agency
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 6 offers Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
Award details come from SAM.gov/FPDS.
About this IDV
The National Institute of Allergy and Infectious Diseases awarded a multiple-award IDIQ to Duke University for Early Phase Clinical Trial Units (EPCTU) on January 14, 2022, with a contract ceiling of $346,610,277 and ultimate completion date of January 13, 2032.
Work is performed in Durham, North Carolina. The originating solicitation, posted November 19, 2020, sought multiple indefinite-delivery contracts to support Phase 0 through Phase III clinical trials of investigational infectious disease products. Eligible offerors compete to conduct domestic and international trials, including administrative support, Phase 0 healthy volunteer studies, Phase I healthy volunteer studies, Phase I special population studies, and Phase II or III patient studies. NAICS codes 541715 and 541712 apply, with PSC codes R425 and R499.
The period of performance runs for seven years from January 2022 through January 13, 2032. Task order activity under this IDIQ includes Task Order 75N93022F00001 Base Award, issued January 14, 2022, valued at $1,963,927, for Task Area A covering administrative and overall clinical operations support and concept development. The task order is priced on a cost-no-fee basis.
Task orders
| Task order | Ordering agency | Obligated | Awarded |
|---|---|---|---|
| Task order 75N93022F00001 base award | National Institute of Allergy and Infectious Diseases (NIH) | $764,407 |
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Other Administrative Action | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Original award | $0 |
Quick answers
Who was awarded contract 75N93022D00019?
75N93022D00019 was awarded to Duke University by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on January 14, 2022.
How much is contract 75N93022D00019 worth?
Orders under 75N93022D00019 have obligated $764,407. Their combined potential value, with all options, is $1,963,927. 75N93022D00019's own ceiling is $346,610,277.
How many orders have been placed under contract 75N93022D00019?
1 order has been placed under 75N93022D00019, the latest on January 14, 2022.
Who can order from contract 75N93022D00019?
75N93022D00019 is a multiple award indefinite delivery contract. Only the awarding agency can place orders on it.
Is contract 75N93022D00019 part of a contract vehicle?
Yes. 75N93022D00019 is part of Early Phase Clinical Trial Units (EPCTU).
Was contract 75N93022D00019 competed?
The extent of competition for 75N93022D00019 was full and open competition. The government received 6 offers.
On GovTribe
See this IDV's full record
- Every order and transaction
- The awardee's other awards and teaming partners
- Similar IDVs and recompete opportunities
- Ask GovTribe AI about this IDV